The breast cancer medication Arimidex beats tamoxifen when it comes to preventing recurrences of hormone-receptor-positive breast cancer in postmenopausal women, a new study suggests. Researchers say Arimidex improved disease-free survival by 15 percent compared with tamoxifen. And the medication continued to work even three years after stopping therapy.
Read moreThe blogwaves were buzzing recently with the news that tamoxifen (nolvadex), the once (and perhaps future) king of breast cancer prevention... Read more »
Question: Are there currently any clinical trials for premenopausal women/women diagnosed under 40 on the use of aromatase inhibitors vs.... Read more »
The American Society of Clinical Oncology (ASCO), over 25,000 members strong, includes representatives from all areas of cancer care:... Read more »
Tamoxifen, or Arimidex/Aromasin/Femara? Which one’s going to keep my cancer from coming back? After years of rumor and equivocation, the... Read more »
Q. I've been on tamoxifen for a couple of years, and now my doctor is switching me to an aromatase inhibitor. I understand how... Read more »
Source: Breastcancer.org
Arimidex (chemical name: anastrozole) is an aromatase inhibitor approved by the U.S. Food and Drug Administration (FDA) to treat: post-menopausal... Read more »
Source: First DataBank
Generic Name: ANASTROZOLE - ORAL Pronounced: (an-AS-TROE-zole) Interactions Your healthcare professionals (e.g., doctor or pharmacist) may already... Read more »